Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid's Q1 Revenue Jumps 27 Percent; Clinical Market Becoming 'Key Driver'

NEW YORK (GenomeWeb News) — Cepheid today said first-quarter revenues increased 27 percent as R&D spending rose 19 percent and profit declined around 6 percent.
Total receipts for the three months ended March 31 increased to $25.5 million from $20.1 million year over year.
Cepheid said instrument sales rose around 50 percent to $.8 million; reagent and disposable sales increased 3 percent to $15.2 million; contract revenues nearly tripled to $1.9 million; and government and government-sponsored research revenue rose five-fold to $1.6 million. The company said clinical products more than doubled to $7.43 million.
Cepheid CEO John Bishop said the clinical market is “emerging as the key driver to the growth of our business with a substantial level of opportunity.” Bishop added that the company expects its industrial and biothreat markets to “provide a continuing base of sales but growth rates will likely vary.”
R&D spending rose to $6.9 million from $5.8 million year over year.
The company said first-quarter profit fell to $6.2 million from $6.7 million in the year-ago period.
Cepheid said it had around $7.8 million in cash and cash equivalents, and $45.8 million in marketable securities.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.